Vinay Prasad abruptly resigned as director of the FDA's Center for Biologics Evaluation and Research (CBER) amid controversy surrounding gene therapy approvals and policy disputes. His tenure saw contentious decisions on Sarepta Therapeutics’ Duchenne muscular dystrophy treatment Elevidys, leading to shipment holds and policy reversals. Prasad’s departure triggered notable biotech stock rallies, reflecting market optimism yet uncertainty about future FDA regulatory approaches. The political pressure behind his exit underscores the challenges balancing scientific rigor with external influence at the agency.